Eisai Co., Ltd.

4523

JP3160400002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:34:42 2024-04-19 am EDT			5-day change	1st Jan Change
5,901 ^JPY	+1.32%		-1.14%	-16.32%

Apr. 01	Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	MT
Apr. 01	BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	MT

Eisai : European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) for Patients With Certain Types of Endometrial CarcinomaFirst Combination of Tyrosine Kinase Inhibitor with Immunotherapy Approved in Europe for Adult Patients With Advanced or Recurrent Endometrial Carcinoma With Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy in Any Setting and Who Are Not Candidates for Curative Surgery or Radiation Approval Based on Study 309/KEYNOTE-7

November 28, 2021 at 06:40 pm EST

For Print
November 29, 2021

Full text

News release searchSearch

Attachments

Original Link
Original Document
Permalink

Disclaimer

Eisai Co. Ltd. published this content on 29 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 November 2021 23:39:03 UTC.

Latest news about Eisai Co., Ltd.

Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	Apr. 01	MT
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	Apr. 01	MT
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	Mar. 31	CI
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	Mar. 22	MT
Lifenet to Launch Dementia-Focused Insurance Product in April	Mar. 22	MT
Jefferies Adjusts Eisai’s Price Target to 6,300 Yen From 7,500 Yen, Keeps at Hold	Mar. 11	MT
BioArctic AB and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	Mar. 11	CI
US FDA delays Lilly Alzheimer's drug decision, calls for advisory panel	Mar. 08	RE
Transcript : Eisai Co., Ltd. - Special Call	Mar. 07
Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected	Mar. 07	RE
RMed Online Ltd. announced that it has received funding from Eisai Co., Ltd.	Mar. 05	CI
Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®	Feb. 22	CI
Biogen expects to return to profit growth this year	Feb. 13	RE
Proteins may predict who will get dementia 10 years later, study finds	Feb. 12	RE
Eisai’s Attributable Profit Down 25.6% in Fiscal Nine Months	Feb. 06	MT
Transcript : Eisai Co., Ltd., Q3 2024 Earnings Call, Feb 06, 2024	Feb. 06
Eisai to Roll Out Alzheimer's Drug in China	Feb. 05	MT
Eisai expects 1,500 Alzheimer's patients in China launch, sees 'huge' growth	Feb. 04	RE
Biogen to discontinue development of older Alzheimer's drug Aduhelm	Jan. 31	RE
Eisai's China Arm Seen to Launch Alzheimer's Treatment in July	Jan. 18	MT
European Medicines Regulator to Discuss Marketing Authorization for BioArctic's Alzheimer's Disease Drug	Jan. 11	MT
Biogen, Eisai Receive Approval for Alzheimer's Treatment Leqembi in China	Jan. 10	MT
Eisai Co. Receives Approval in China for Alzheimer’s Drug, Eyes July Sales Launch	Jan. 09	MT
BioArctic's Partner Obtains Marketing Authorization for Leqembi in China	Jan. 09	MT
Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China	Jan. 09	CI

Chart Eisai Co., Ltd.

Duration

Period

More charts

Company Profile

Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (87.7%): prescribed drugs, health products, etc.; - other (12.3%): food additives, chemical products, etc. Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q4 2024 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Eisai Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5,901 JPY

Average target price

8,193 JPY

Spread / Average Target

+38.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EISAI CO., LTD.	-16.32%	10.8B
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals

Eisai Co., Ltd.

Equities

4523

JP3160400002

Pharmaceuticals

EPS Revisions